Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer
Conclusion. Preliminary results revealed that pioglitazone adjunacy with celecoxib may be an effective chemo-preventive agent against NNK induce NSCLC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Actos | Brain | Cancer | Cancer & Oncology | Celebrex | Chemotherapy | Drugs & Pharmacology | Investigational New Drugs | Lung Cancer | Neurology | Nicotine | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Study